Global De-Identified Health Data Market Growth Accelerates: Strategic Forecast Predicts $14.4 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the De-Identified Health Data Industry Market Size Be by 2025?
In recent years, the market size for de-identified health data has seen a significant increase. It is projected to expand from $8.20 billion in 2024 to $9.20 billion in 2025, with a compound annual growth rate (CAGR) of 12.2%. This growth in the historical duration can be traceable to the increased acceptance of electronic health records, heightened consciousness of patient data privacy, the boom in usage of healthcare analytics, inflating research on managing population health, enlargement of health information technology systems, and the escalating utilization of data in clinical trials.

What's the Long-Term Growth Forecast for the De-Identified Health Data Market Size Through 2029?
In the ensuing years, the market size for de-identified health data is projected to substantially increase. An anticipated growth to a massive $14.40 billion is projected by 2029, with a compound annual growth rate (CAGR) of 11.8%. Factors like the burgeoning use of artificial intelligence in healthcare, rising need for real-world proof in drug creation, increased emphasis on the secondary use of healthcare data, significant surge in demand for privacy-focused technology and a growing need for precision medicine are all major contributors to growth in this forecast period. Key emerging trends in this forecast span include the creation of data privacy protocols, the development of machine learning workflows, integration with electronic health records and population health platforms, and advancement in data anonymization methods.

View the full report here:
https://www.thebusinessresearchcompany.com/report/de-identified-health-data-global-market-report

What Are the Key Growth Drivers Fueling the De-Identified Health Data Market Expansion?
Anticipations of the growth of the de-identified health data market are driven by the escalating uptake of electronic health records (EHRs). These are digital compilations of a patient's full medical history, encompassing diagnosis, treatment, medications, lab results and other vital health data. They are securely stored and shared only with authorized medical service providers. The increasing prevalence of these electronic health records owes much to their capacity to improve patient care and safety by offering accurate, up-to-the-minute access to extensive medical records. The incorporation of de-identified health data amplifies the effectiveness of EHRs. It fosters data sharing and intricate analytics without compromising patients' privacy, thus leading to improved clinical decisions and health care results. For example, the UK Department of Health and Social Care forecasted in June 2022 that all NHS trusts are projected to have EHRs in place by March 2025. This marks a sizeable increase from the 90% adoption rate reported in December 2023. Consequently, the expanding uptake of electronic health records (EHRs) is the catalyst for the de-identified health data market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28191&type=smp

What Are the Key Trends Driving De-Identified Health Data Market Growth?
Significant firms in the de-identified health data market are concentrating on the creation of sophisticated solutions, like real-world biomarker coverage applications, to aid in evidence-based health decisions. These applications use de-identified data from patients to track and evaluate biomarker patterns and efficiency in different populations beyond clinical studies. This allows scientists and health service providers to comprehend disease trends and responses to treatments. For example, Datma Inc., a health technology company situated in the US, rolled out the Federated Biomarker Explorer in July 2025. The free tool is aimed at pharmaceutical teams, enabling them to validate real-world biomarker coverage across Datma's federated network of data contributing partners swiftly. This tool offers aggregate insights at the cohort level into biomarker existence, allowing teams to evaluate coverage swiftly without contracts or IT support. It also supports secure integration of the user's data for overlap studies and aids in preliminary feasibility evaluations with clinical and demographic filters, validating if datasets incorporate the necessary patient populations before allocating resources.

How Is the De-Identified Health Data Market Segmented?
The de-identified health data market covered in this report is segmented as

1) By Type: Clinical Data, Genomic Data, Patient Demographics, Prescription Data, Hospital And Provider Data, Pharmacogenomic Data
2) By Application: Clinical Research And Trials, Public Health, Precision Medicine, Health Economics And Outcomes Research (HEOR), Population Health Management, Drug Discovery And Development, Healthcare Quality Improvement, Insurance Underwriting And Risk Assessment, Other Applications
3) By End-User: Pharmaceutical Companies, Biotechnology Firms, Healthcare Providers, Insurance Companies Or Healthcare Payers, Research Institutions, Government Agencies, Other End-Users

Subsegments:
1) By Clinical Data: Electronic Health Records, Medical Imaging Data, Laboratory Test Results, Surgical Reports, Pathology Reports, Vital Signs Measurements
2) By Genomic Data: Whole Genome Sequencing Data, Exome Sequencing Data, Single Nucleotide Polymorphism Data, Gene Expression Profiles, Epigenetic Data
3) By Patient Demographics: Age Information, Gender Information, Ethnicity Information, Geographic Location, Socioeconomic Status, Marital Status
4) By Prescription Data: Medication Orders, Dosage Information, Prescription Refill History, Drug Allergies, Pharmacy Dispensation Records
5) By Hospital And Provider Data: Provider Performance Metrics, Care Delivery Outcomes, Billing And Claims Data, Resource Utilization Data
6) By Pharmacogenomic Data: Gene-Drug Interaction Data, Adverse Drug Reaction Data, Personalized Therapy Response Data, Drug Efficacy Variation Data

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28191&type=smp

Which Companies Are Leading the Charge in De-Identified Health Data Market Innovation?
Major companies operating in the de-identified health data market are UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc, ICON Public Limited Company, Datavant Inc, Premier Inc., iMerit Technology Services Pvt. Ltd., Tempus Labs Inc., Medidata Solutions Inc., Veradigm Inc., Flatiron Health, Merative LP, Komodo Health Inc., Shaip Inc., Truveta Inc., Evidation Health Inc., TriNetX Inc., Clarify Health Solutions Inc., Akrivia Health Ltd., Gradient Health Inc.

Which Regions Are Leading the Global De-Identified Health Data Market in Revenue?
North America was the largest region in the de-identified health data market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in de-identified health data report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28191

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.